Angiotensin receptor neprilysin inhibition versus individualized RAAS blockade: design and rationale of the PARALLAX trial

AIMS: Although the effect of the angiotensin receptor blocker neprilysin inhibitor (ARNI) sacubitril/valsartan on heart failure (HF) hospitalizations and cardiovascular death has been evaluated, its effects on functional capacity in patients with HF and ejection fraction (EF) >40% has yet to be d...

Descripción completa

Detalles Bibliográficos
Autores principales: Wachter, Rolf, Shah, Sanjiv J., Cowie, Martin R., Szecsödy, Peter, Shi, Victor, Ibram, Ghionul, Zhao, Ziqiang, Gong, Jianjian, Klebs, Sven, Pieske, Burkert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Study Designs
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7261527/
https://www.ncbi.nlm.nih.gov/pubmed/32297449
http://dx.doi.org/10.1002/ehf2.12694

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7261527/
https://www.ncbi.nlm.nih.gov/pubmed/32297449
http://dx.doi.org/10.1002/ehf2.12694

Ejemplares similares